NEUROMIND LABS LTD

Executive Summary

NEUROMIND LABS LTD, a newly incorporated micro-entity, is showing early signs of financial strain with negative working capital and net assets. While typical for startups investing in growth, these symptoms require close management of liquidity and timely capital support to improve financial resilience. With focused cost control and revenue development, the company can stabilize and progress toward sustainable health.

NEUROMIND LABS LTD - Analysis Report

Company Number: 14759748

Analysis Date: 2025-07-20 18:28 UTC

Financial Health Assessment for NEUROMIND LABS LTD (as of 31 March 2024)

---

1. Financial Health Score: D

Explanation:
NEUROMIND LABS LTD is currently exhibiting signs of financial distress, primarily due to negative net assets and net current liabilities. While the company is in its infancy (incorporated in 2023) and classified as a micro-entity, the current financial indicators suggest it is operating with more short-term liabilities than current assets, which is a warning sign for liquidity and sustainability.

---

2. Key Vital Signs (Critical Metrics)

Metric	Value	Interpretation
Current Assets	£35,718	Cash and other short-term assets available
Current Liabilities	£42,549	Short-term debts due within one year
Net Current Assets	-£6,831	Negative working capital indicates liquidity stress
Net Assets (Total Equity)	-£7,080	Negative equity implies liabilities exceed assets
Shareholders’ Funds	-£7,080	Owners’ stake is negative, representing accumulated losses or funding gaps
Number of Employees	1	Very small scale, typical for a micro-entity

Interpretation of Vital Signs:

• Negative Net Current Assets ("working capital deficit") is a classic symptom of cash flow strain, potentially leading to difficulty in meeting short-term obligations.
• Negative Net Assets/Shareholders’ Funds is akin to a "balance sheet illness," indicating the company’s liabilities surpass its assets, which can threaten solvency if it persists.
• The company’s sole director and 100% shareholder is the founder, suggesting a closely held business but also concentration risk.

---

3. Diagnosis: Financial Condition Assessment

NEUROMIND LABS LTD is in the early stages of development, which often involves initial investment phases and operational losses. The financial statements show:

• Liquidity Stress: Negative net current assets highlight a cash flow imbalance; the company has more short-term debts than readily available assets. This condition can impair the company’s ability to pay suppliers, staff, or other creditors on time—a symptom of financial distress.
• Solvency Concern: Negative net assets indicate the company’s accumulated losses or expenditures exceed its resources, a sign of financial weakness. This could be due to initial startup costs, investment in product development, or early operating losses typical in tech startups.
• Micro-Entity Status: As a micro-entity under FRS 105, the company benefits from simplified reporting but still must monitor cash flows carefully to avoid liquidity crises.
• No Audit & Limited Disclosure: While exempt from audit, the lack of comprehensive financial detail limits deeper insight into profitability, revenue trends, or cash flow statements, which are critical for full health assessment.

Overall, the company is in a fragile financial state but not yet in crisis, assuming ongoing shareholder support and/or incoming revenue streams.

---

4. Recommendations: Actions to Improve Financial Wellness

• Improve Working Capital Management:

  • Negotiate extended payment terms with creditors to ease immediate cash outflows.
  • Accelerate collection of any receivables to boost cash inflows.
  • Regularly monitor cash flow forecasts to anticipate and plan for liquidity needs.

• Capital Injection or Funding:

  • The sole shareholder might consider injecting additional equity or arranging short-term financing to cover the working capital gap and improve the balance sheet.
  • Explore government grants or startup funding schemes available to tech firms in the UK.

• Cost Control:

  • Review and minimize operating expenses to reduce cash burn, especially given only one employee currently.
  • Delay non-essential expenditures until the company achieves a healthier cash flow.

• Revenue Generation:

  • Focus on accelerating sales or contract wins in software development and IT services (SIC 62090, 62012) to move towards positive cash flow and profitability.

• Regular Financial Review:

  • Maintain monthly management accounts to track financial health indicators closely.
  • Consider external advisory support to strengthen financial planning and risk management.

• Prepare for Next Filings:

  • Ensure timely submission of accounts and confirmation statements to avoid penalties and maintain regulatory compliance.

---

Medical Analogy Summary

NEUROMIND LABS LTD currently shows symptoms of financial distress, with a "healthy cash flow" yet to be established, much like a patient in the early stages of illness needing prompt treatment. The negative working capital is a warning sign akin to a low pulse rate—urgent attention to liquidity is required to avoid a deeper crisis. With careful management and possible "nutritional support" via capital injection, the company can recover and strengthen its financial "immune system."

---